Wikidata

(Q64123164)

English

A Study of ABT-414 in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification

clinical trial

In more languages

Statements

short name
Intellance1 (English)
0 references
title
A Randomized, Placebo Controlled Phase 3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1) (English)
0 references
country
Argentina
0 references
Australia
0 references
Austria
0 references
Belgium
0 references
Brazil
0 references
Canada
0 references
Colombia
0 references
France
0 references
Germany
0 references
Republic of Ireland
0 references
Israel
0 references
Italy
0 references
Mexico
0 references
Netherlands
0 references
New Zealand
0 references
Portugal
0 references
Singapore
0 references
South Africa
0 references
Spain
0 references
Switzerland
0 references
Taiwan
0 references
United Kingdom
0 references
start time
7 December 2015
0 references
end time
18 March 2020
0 references
number of participants
640
0 references
minimum age
18 year
0 references
maximum age
99 year
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q64123164&oldid=1857553740"